Rey G, Bounebache K, Rondet C. Causes of deaths data, linkages and big data perspectives. J Forensic Leg Med. 2018 Jul;57:37–40.
Chazal T, Lhote R, Rey G, Haroche J, Eb M, Amoura Z, et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmun Rev. 2018 Dec;17(12):1219–24.
Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, et al. Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). Rheumatology (Oxford). 2018 Jun 1;57(6):1047–55.
Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239–48.
Affret A, Severi G, Dow C, Mancini FR, Rey G, Delpierre C, et al. Socio-economic factors associated with an increase in fruit and vegetable consumption: a 12-year study in women from the E3N-EPIC study. Public Health Nutr. 2018;21(4):740–55.
Antero-Jacquemin J, Pohar-Perme M, Rey G, Toussaint JF, Latouche A. The heart of the matter: years-saved from cardiovascular and cancer deaths in an elite athlete cohort with over a century of follow-up. Eur J Epidemiol. 2018 Jun;33(6):531–43.
Clergue F, Auroy Y, Pequignot F, Jougla E, Lienhart A, Laxenaire MC. Evolution of the anaesthetic workload--the French experience. Best Pract Res Clin Anaesthesiol. 2002 Sep;16(3):459–73.
Hoffmann R, Plug I, Khoshaba B, McKee M, Mackenbach JP, AMIEHS working group. Amenable mortality revisited: the AMIEHS study. Gac Sanit. 2013 Jun;27(3):199–206.
Menvielle G, Rey G, Jougla E, Luce D. Diverging trends in educational inequalities in cancer mortality between men and women in the 2000s in France. BMC Public Health. 2013 Sep 10;13(1):823.
Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. Int J Public Health. 2013 Aug 29;
Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in medical care and mortality trends from four circulatory diseases between 1970 and 2005. Eur J Public Health. 2013 Oct;23(5):852–7.
Marijon E, Tafflet M, Antero-Jacquemin J, El Helou N, Berthelot G, Celermajer DS, et al. Mortality of French participants in the Tour de France (1947-2012). Eur Heart J. 2013 Oct;34(40):3145–50.
Rafnsson SB, Bhopal RS, Agyemang C, Fagot-Campagna A, Harding S, Hammar N, et al. Sizable variations in circulatory disease mortality by region and country of birth in six European countries. Eur J Public Health. 2013 Aug;23(4):594–605.
Ghosn W, Kassie D, Jougla E, Rican S, Rey G. Spatial interactions between urban areas and cause-specific mortality differentials in France. Health Place. 2013 Nov;24:234–41.
Ghosn W, Kassié D, Jougla E, Salem G, Rey G, Rican S. Trends in geographic mortality inequalities and their association with population changes in France, 1975-2006. Eur J Public Health. 2013 Oct;23(5):834–40.
Mackenbach JP, Hoffmann R, Khoshaba B, Plug I, Rey G, Westerling R, et al. Using “amenable mortality” as indicator of healthcare effectiveness in international comparisons: results of a validation study. J Epidemiol Community Health. 2013 Feb;67(2):139–46.
Kernéis S, Boëlle PY, Grais RF, Pavillon G, Jougla E, Flahault A, et al. Mortality trends in systemic sclerosis in France and USA, 1980-1998: an age-period-cohort analysis. Eur J Epidemiol. 2010;25(1):55–61.
Ziadé N, Jougla E, Coste J. Population-level impact of osteoporotic fractures on mortality and trends over time: a nationwide analysis of vital statistics for France, 1968-2004. Am J Epidemiol. 2010 Oct 15;172(8):942–51.
Béjot Y, Aouba A, de Peretti C, Grimaud O, Aboa-Eboulé C, Chin F, et al. Time trends in hospital-referred stroke and transient ischemic attack: results of a 7-year nationwide survey in France. Cerebrovasc Dis. 2010;30(4):346–54.